Cover Image
市場調查報告書

顯微多發性血管炎(MPA):開發平台分析

Microscopic Polyangiitis (MPA) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 302487
出版日期 內容資訊 英文 47 Pages
訂單完成後即時交付
價格
Back to Top
顯微多發性血管炎(MPA):開發平台分析 Microscopic Polyangiitis (MPA) - Pipeline Review, H2 2016
出版日期: 2016年07月20日 內容資訊: 英文 47 Pages
簡介

顯微多發性血管炎(MPA)目前仍是未知的疾病,是血管發炎造成的發病,並損及內臟器官。最容易受到MPA侵害的部位有腎臟和肺,神經,皮膚,關節等。主要的症狀有呼吸急促和咳嗽,發熱,食慾不振,皮疹,肌肉痛·關節痛等。此外主要治療方法有免疫抑制療法等。

本報告提供全球各國治療顯微多發性血管炎(MPA)所用的開發中產品之開發情形相關分析,提供您開發中產品的開發·上市的最新趨勢,及臨床實驗各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等調查,並將結果概述為以下內容。

目錄

簡介

  • 分析範圍

顯微多發性血管炎概要

治療藥的開發

  • 顯微多發性血管炎開發中產品:概要
  • 顯微多發性血管炎開發中產品:比較分析

企業正在開發的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的開發企業

  • Aprogen, Inc.
  • ChemoCentryx, Inc.
  • Epirus Biopharmaceuticals, Inc.
  • GlaxoSmithKline Plc
  • Panacea Biotec Limited
  • Sandoz International GmbH
  • Teijin Pharma Limited

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • belimumab
  • CCX-168
  • immune globulin (human)
  • rituximab biosimilar
  • rituximab biosimilar
  • rituximab biosimilar
  • rituximab biosimilar

最新開發平台趨勢

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8259IDB

Summary

Global Markets Direct's, 'Microscopic Polyangiitis (MPA) - Pipeline Review, H2 2016', provides an overview of the Microscopic Polyangiitis (MPA) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Microscopic Polyangiitis (MPA), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Microscopic Polyangiitis (MPA) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Microscopic Polyangiitis (MPA)
  • The report reviews pipeline therapeutics for Microscopic Polyangiitis (MPA) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Microscopic Polyangiitis (MPA) therapeutics and enlists all their major and minor projects
  • The report assesses Microscopic Polyangiitis (MPA) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Microscopic Polyangiitis (MPA)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Microscopic Polyangiitis (MPA)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Microscopic Polyangiitis (MPA) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
    • Microscopic Polyangiitis (MPA) Overview
    • Therapeutics Development
  • Pipeline Products for Microscopic Polyangiitis (MPA) - Overview
  • Microscopic Polyangiitis (MPA) - Therapeutics under Development by Companies
  • Microscopic Polyangiitis (MPA) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Microscopic Polyangiitis (MPA) - Products under Development by Companies
  • Microscopic Polyangiitis (MPA) - Companies Involved in Therapeutics Development
    • ChemoCentryx, Inc.
    • Coherus BioSciences, Inc.
    • GlaxoSmithKline Plc
    • Panacea Biotec Limited
    • Sandoz International GmbH
    • Teijin Pharma Limited
  • Microscopic Polyangiitis (MPA) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • belimumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CCX-168 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • immune globulin (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rituximab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rituximab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rituximab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Microscopic Polyangiitis (MPA) - Dormant Projects
  • Microscopic Polyangiitis (MPA) - Product Development Milestones
    • Featured News & Press Releases
      • Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis
      • Jun 03, 2014: ChemoCentryx's CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation in ANCA-Associated Diseases by the FDA
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Microscopic Polyangiitis (MPA), H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Microscopic Polyangiitis (MPA) - Pipeline by ChemoCentryx, Inc., H2 2016
  • Microscopic Polyangiitis (MPA) - Pipeline by Coherus BioSciences, Inc., H2 2016
  • Microscopic Polyangiitis (MPA) - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Microscopic Polyangiitis (MPA) - Pipeline by Panacea Biotec Limited, H2 2016
  • Microscopic Polyangiitis (MPA) - Pipeline by Sandoz International GmbH, H2 2016
  • Microscopic Polyangiitis (MPA) - Pipeline by Teijin Pharma Limited, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Microscopic Polyangiitis (MPA) - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Microscopic Polyangiitis (MPA), H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top